Commvault Systems Inc vs Medpace Holdings Inc — how do they compare? Commvault Systems Inc trades at $141.3 (market cap $5.78B), while Medpace Holdings Inc trades at $600.48 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 2.9× Commvault Systems Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Commvault Systems Inc nearer its low. Which is the better fit depends on your goals.
| CVLT | MEDP | |
|---|---|---|
Market Cap | $5.78B | $16.90B |
Sector | Technology | Technology |
52-Week High | $195.41 | $620.59 |
52-Week Low | $75.18 | $393.42 |
Enterprise Value | $5.76B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $140.52, up 0.78% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 81% gross margins, and 32.77% ROE, though valuation metrics appear elevated with P/E at 89.35. Recent news highlights positive developments including Threat Scan integration with Google and strong Q1 2027 results with 16% subscription revenue growth.
CVLT presents growth potential with 22% ARR growth and analyst consensus target of $172.40 (23% upside), but faces risks from fiduciary investigations and high valuation multiples. The stock's technical strength and fundamental execution support bullish sentiment, though investors should monitor the ongoing legal scrutiny and margin compression from 7.64% to 5.61% net margin projection.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →